QIAGEN NV ISIN: NL0015001WM6 WKN: N72482149 Asset Class: Stock



Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in VenIo, the Netherlands.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20	2 2	202	21
Financial figures	Assets Liabilities and equity Assets Liabilities and equity		Assets Liabilities and equity			
Current assets	2,147,560,000		2,393,952,000		2,109,602,000	
Common stock capital		2,702,000		2,702,000		2,702,000
Fixed assets	3,967,630,000		3,893,783,000		4,037,352,000	
Equity capital of a company		3,807,764,000		3,466,611,000		3,096,550,000
Cash and cash equivalents	668,084,000		730,669,000		880,516,000	
Accrued liabilities		12,100,000		11,900,000		0
Other assets	-		-		-	
Current liabilities		1,079,293,000		974,523,000		1,517,470,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,228,133,000		1,846,601,000		1,532,934,000
Different income		-		-		-
Other liabilities		202,346,000		273,897,000		324,665,000
Total assets	6,115,190,000	6,115,190,000	6,287,735,000	6,287,735,000	6,146,954,000	6,146,954,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	5,967	6,178	6,028
Equity ratio	62.27%	55.13%	50.38%
Debt-equity ratio	60.60%	81.38%	98.51%

Others

	2023	2022	2021
Tax Expense Rate	20.59%	17.44%	18.09%

QIAGEN NV ISIN: NL0015001WM6 WKN: N72482149 Asset Class: Stock

2023 2022 2021 Turnover 1,965,311,000 2,141,518,000 2,251,657,000 Net income 341,303,000 423,211,000 512,599,000 EBIT 372,737,717 496,275,142 618,503,186 625,833,000 Operating income before taxes 429,809,000 512,601,000 **Cash Flow** 715,264,000 639,001,000 459,455,000 Net interest income 25,582,000 -25,600,000 -44,922,000 **Research and development expenses** 189,964,000 198,511,000 189,859,000 113,234,000 **Income taxes** 88,506,000 89,390,000 Result from investments in subsidaries, associates and other **Revenues per employee** 303,706 319,633 344,435

Board of Directors

Income statement

Lawrence Rosen	Chairman of Supervisory Board
Elaine Mardis	Member of Supervisory Board
Eva Pisa	Member of Supervisory Board
Metin Colpan	Member of Supervisory Board
Ross Levine	Member of Supervisory Board
Toralf Haag	Member of Supervisory Board
Bert van Meurs	Member of Supervisory Board
Elizabeth Tallett	Member of Supervisory Board
Eva van Pelt	Member of Supervisory Board
Stephen Rusckowski	Member of Supervisory Board

Members of Management Board

Thierry Bernard	Chairman of Managing Board	
Jonathan Sheldon	Member of Executive Committee	
Philipp von Hugo	Member of Executive Committee	
Thomas Schweins	Member of Executive Committee	
Ulrich Schriek	Member of Executive Committee	
Antonio Santos	Member of Executive Committee	
Jean-Pascal Viola	Member of Executive Committee	
John Gilardi	Member of Executive Committee	
Lezette Young	Member of Executive Committee	
Nedal Safwat	Member of Executive Committee	
Roland Sackers	Member of Executive Committee	
Stephany Foster	Member of Executive Committee	